

Title: Blood Neurofilament Light Chain Measurement toward Clinical Application: A Review

Shoshin Akamine^{1,2*} and Takashi Kudo^{1,2}

¹Department of Mental Health Promotion, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

²Health and Counseling Center, Osaka University, Toyonaka, Osaka, Japan

Abstract

Bi

Å

KP

-

b

b

paved the way for assessing neuroaxonal injury using blood tests [3-5].

Blood NFL level in neurological disease

According to previous reports, blood NFL levels are elevated in various neurologic conditions, including multiple sclerosis (MS), stroke, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and traumatic brain injury (TBI). Blood NFL levels can also be used to monitor disease severity and predict long-term outcomes. In specific situations, it may help support a differential diagnosis. The most studied neurological disease with blood NFL analysis is MS.

The current role of biomarkers to monitor neuronal injury is limited. Usually, it is evaluated by MRI, but its high cost and long scan time limit its utility. Blood NFL level elevation is reported to be correlated with relapse of symptoms, as well as new lesions on MRI scans, in both progressive and relapsing MS in many studies [3, 5-10]. The decrease in blood NFL levels was observed after treatment, indicating its potential for monitoring treatment effect. [8,11,12] Blood NFL level responds to anti-inflammatory therapies 3 to 6 months after their initiation, with its degree of difference reflecting treatment efficacy. [7] Blood NFL level is also elevated after stroke. It takes several days to rise, is correlated with symptom severity and lesion size, and can predict functional outcomes and the onset of postinfarct depression. The elevation can take several hours to more than a week, and it remains elevated for several months. Patients with ALS have higher blood NFL levels 1 year before symptom onset, thus helping in predicting incidence. Blood NFL levels can differentiate ALS from its mimics, and it can be an independent predictor of clinical prognosis. In FTD, a higher blood NFL level is

*Corresponding author:

E-mail: kudo@psy.med.osaka-u.ac.jp

Received: 03-Jan-2022, Manuscript No. jceni-21-25152; **Editor assigned:** 05-Jan-2022, PreQC No. jceni-21-25152(PQ); **Reviewed:** 19-Jan-2022, QC No. jceni-21-25152; **Revised:** 24-Jan-2022, Manuscript No. jceni-21-25152(R); **Published:** 31-Jan-2022, DOI: 10.4172/jceni.1000139

Citation: Akamine S, Kudo T (2022) Title: Blood Neurofilament Light Chain Measurement toward Clinical Application: A Review. J Clin Exp Neuroimmunol, 7: 139.

Copyright: © Akamine S, Kudo T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits original author and source are credited.

observed at symptom onset when compared to that in healthy controls. It can be used as a predictor of prognosis and differentiate FTD with behavioral symptoms from primary psychiatric disorders. TBI is also reported to be related to elevated blood NFL levels. In this case, blood NFL correlates with the number of head impacts and is associated with the outcome a year. An increase in blood NFL is also observed in patients with Parkinson's disease (PD) and Alzheimer's disease (AD); however, the overlap of the levels with healthy controls is Tlood poidu0.6(Tpersbrelly b blyamanyAfeingb0iliFL l0-w 0 -1.2 6dy baccembra is ever, AlzBBBime)Tm.,

idut0.2

11.